Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

Enrico Garaci, Antonio Mastino, Francesca Pica, Cartesio Favalli

Research output: Contribution to journalArticle

Abstract

A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 × 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

Original languageEnglish
Pages (from-to)154-160
Number of pages7
JournalCancer Immunology, Immunotherapy
Volume32
Issue number3
DOIs
Publication statusPublished - May 1990

Fingerprint

Thymosin
Lewis Lung Carcinoma
Cyclophosphamide
Interferons
Neoplasms
Therapeutics
Drug Therapy
Injections
Tumor Burden
Immunotherapy
Lymphocytes
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. / Garaci, Enrico; Mastino, Antonio; Pica, Francesca; Favalli, Cartesio.

In: Cancer Immunology, Immunotherapy, Vol. 32, No. 3, 05.1990, p. 154-160.

Research output: Contribution to journalArticle

@article{591a01a2e5484122abb94bcf9d74637b,
title = "Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice",
abstract = "A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 × 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.",
author = "Enrico Garaci and Antonio Mastino and Francesca Pica and Cartesio Favalli",
year = "1990",
month = "5",
doi = "10.1007/BF01771450",
language = "English",
volume = "32",
pages = "154--160",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

AU - Garaci, Enrico

AU - Mastino, Antonio

AU - Pica, Francesca

AU - Favalli, Cartesio

PY - 1990/5

Y1 - 1990/5

N2 - A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 × 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

AB - A combination treatment with thymosin α1 (200 μg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 × 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025696176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025696176&partnerID=8YFLogxK

U2 - 10.1007/BF01771450

DO - 10.1007/BF01771450

M3 - Article

C2 - 2126987

AN - SCOPUS:0025696176

VL - 32

SP - 154

EP - 160

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -